NCT04257110View on ClinicalTrials.gov

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2024

Conditions
Locally Advanced/Metastatic HER2 Positive Solid Tumors
Interventions
DRUG

BB-1701

BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.

Trial Locations (12)

22031

The Regents of NEXT Virginia, LLC, Fairfax

37203

Sarah Cannon Research, Nashville

94158

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

310003

The First Affiliated Hospital of Zhejiang University, Hangzhou

Unknown

Jiangsu Province Hospital, Nanjin

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Sun Yat-sen Memorial Hospital, Guangzhou

Sir Run Run Shaw Hospital - Zhejiang University School of Medicine, Hangzhou

Zhejiang Cancer Hospital, Hanzhou

Linyi Cancer Hospital, Linyi

Hubei Cancer Hospital, Wuhan

All Listed Sponsors
lead

Bliss Biopharmaceutical (Hangzhou) Co., Ltd

INDUSTRY

NCT04257110 - A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors | Biotech Hunter | Biotech Hunter